Literature DB >> 977997

Synergism between amikacin and cefazolin against Klebsiella: in vitro studies and effect on the bactericidal activity of serum.

J Klastersky, F Meunier-Carpentier, J M Prevost, M Staquet.   

Abstract

Synergism between amikacin and cefazolin was studied in vitro in 20 strains of Klebsiella isolated from clinical material. Several techniques for the demonstration of synergism in vitro were employed. The checkerboard technique with use of bactericidal end points and the killing curves method showed synergism between amikacin and cefazolin for 13 and 15 strains, respectively. The two techniques were in accordance in 12 instances. The data obtained in vitro were correlated with the bactericidal activity in sera from 10 subjects who had received the usual doses of amikacin and cefazolin, alone or in combination. The sera of subjects who received amikacin plus cefazolin were bactericidal at significantly higher dilutions than sera of patients who received cefazolin alone. The increased serum bactericidal activity in subjects receiving amikacin plus cefazolin was observed only for strains against which these antibiotics were synergistic in vitro.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 977997     DOI: 10.1093/infdis/134.3.271

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

1.  Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test.

Authors:  R L White; D S Burgess; M Manduru; J A Bosso
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

Review 2.  Antibiotic combinations: should they be tested?

Authors:  G M Eliopoulos; C T Eliopoulos
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

3.  The bactericidal activity in serum and its prognostic clinical value.

Authors:  J Klastersky
Journal:  Infection       Date:  1983       Impact factor: 3.553

4.  Synergism between aminoglycosides and cephalosporins with antipseudomonal activity: interaction index and killing curve method.

Authors:  H O Hallander; K Dornbusch; L Gezelius; K Jacobson; I Karlsson
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

Review 5.  Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis.

Authors:  Mical Paul; Adi Lador; Simona Grozinsky-Glasberg; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2014-01-07

6.  Rapid diagnosis of Pseudomonas aeruginosa urinary tract infections by radioimmunoassay.

Authors:  R B Kohler; L J Wheat; A White
Journal:  J Clin Microbiol       Date:  1979-02       Impact factor: 5.948

7.  Bronchial secretion levels of amikacin.

Authors:  W L Dull; M R Alexander; J E Kasik
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

8.  Serum bactericidal activity of ceftazidime and cefoperazone alone or in combination with amikacin against Pseudomonas aeruginosa and Klebsiella pneumoniae.

Authors:  Y Van Laethem; H Lagast; J Klastersky
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

Review 9.  Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia.

Authors:  Mical Paul; Yaakov Dickstein; Agata Schlesinger; Simona Grozinsky-Glasberg; Karla Soares-Weiser; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2013-06-29

10.  The pharmaco -, population and evolutionary dynamics of multi-drug therapy: experiments with S. aureus and E. coli and computer simulations.

Authors:  Peter Ankomah; Paul J T Johnson; Bruce R Levin
Journal:  PLoS Pathog       Date:  2013-04-04       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.